Ocuphire Pharma Investor Presentation Deck

6 ● ● Presbyopia VEGA-1 Phase 2 Design Randomized, Double-Masked, Placebo-Controlled, Multi-Center One-Week Trial VEGA-1 17 US sites 150 presbyopia patients 0.75% Nyxol 4 arms Placebo Randomization Visit 1 Baseline Baseline Baseline Baseline Screening Evening Dosing (3-4 doses) Nyxol Nyxol Placebo Placebo Visit 2 (3-6 Days Later) LDP Drop No Treatment LDP Drop No Treatment Treatment Arms Nyxol + LDP Nyxol Alone LDP Alone Placebo Alone Eligibility Criteria Males or females ≥ 40 and ≤ 64 years of age BCDVA of 0.0 LogMAR(20/20 Snellen equivalent) or better in each eye under photopic conditions DCNVA of 0.4 LogMAR (20/50 Snellen equivalent) or worse in photopic conditions in each eye & binocularly Phase 2 Enrollment Completed Feb to May 2021 – 150 Subjects Reported Topline Results End of 2Q21 Clinical trial NCT#04675151. DCNVA = distance-corrected near visual acuity. BCDVA = best corrected distance visual acuity Endpoints Primary: % of subjects with ≥ 3 lines of improvement in distance- corrected near visual acuity comparing Nyxol + LDP vs placebo alone at 1 hour Secondary: ● • % of subjects with ≥ 2 and ≥ 3 lines gained at time points from 30 min to 6 hours in photopic lighting comparing Nyxol + LDP vs placebo, Nyxol alone, and LDP alone No loss of distance vision Pupil diameter at time points Safety and tolerability (redness) ● Ocuphire PHARMA

View entire presentation